CoreCap Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

CoreCap Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27K	Buy	67 +10	+18%	+$333	﹤0.01%	2508
2026 Q1	$1.72K	Sell	57 -500	-90%	-$16.1K	﹤0.01%	2445
2025 Q4	$17.4K	Buy	557 +513	+1,166%	+$12.6K	﹤0.01%	1735
2025 Q3	$889	Hold	44	–	–	﹤0.01%	2500
2025 Q2	$737	Hold	44	–	–	﹤0.01%	2462
2025 Q1	$676	Hold	44	–	–	﹤0.01%	2609
2024 Q4	$970	Sell	44 -1,000	-96%	-$18.2K	﹤0.01%	2380
2024 Q3	$18.8K	Buy	+1,044	New	+$18.3K	﹤0.01%	1588
2024 Q2	–	Sell	-1,044	Closed	-$14.7K	–	2474
2024 Q1	$14.7K	Buy	+1,044	New	+$13.2K	﹤0.01%	1605
2022 Q4	$1.82K	Buy	+200	New	+$1.75K	﹤0.01%	1953
2022 Q1	–	Sell	-71	Closed	-$1K	–	1926
2021 Q4	$1K	Buy	+71	New	+$641	﹤0.01%	2251

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

CoreCap Advisors's TEVA Position: Q2 2026 in Review

CoreCap Advisors increased its Teva Pharmaceuticals (TEVA) stake by 18% in Q2 2026, buying an estimated $333 and bringing the position to 67 shares worth $2.27K. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

CoreCap Advisors first reported a position in TEVA in Q4 2021 and has held it in 11 quarters since. The position peaked at $18.8K in Q3 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

CoreCap Advisors held 67 shares of Teva Pharmaceuticals worth $2.27K as of Q2 2026.
CoreCap Advisors bought 10 Teva Pharmaceuticals shares in Q2 2026, an estimated $333.
Teva Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2508 holding.
CoreCap Advisors first reported a position in Teva Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
CoreCap Advisors's Teva Pharmaceuticals position peaked at $18.8K in Q3 2024.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.